LLY Novinky na Forexu
Eli Lilly Q2 Results Top Estimates; Boosts FY24 Outlook
Drugmaker Eli Lilly reported Thursday a net profit for the second quarter that surged 68 percent from last year, reflecting strong Mounjaro, Zepbound and Verzenio sales as well as higher realized prices. Both adjusted earnings per share and revenues topped analysts' expectations. The company also raised its guidance for the full-year 2024.
RTTNews
|
Před 79 dny
Eli Lilly Again Boosts FY24 Outlook - Update
While reporting financial results for the second quarter on Thursday, drugmaker Eli Lilly and Co. (LLY) raised its earnings, adjusted earnings and revenue guidance for the full-year 2024, primarily driven by the strong performance of Mounjaro and Zepbound, as well as the company's non-incretin medicines.
RTTNews
|
Před 79 dny
Eli Lilly Collaborates With OpenAI To Use Generative AI To Invent Novel Antimicrobials
Eli Lilly and Co. (LLY) announced Tuesday a collaboration with OpenAI that will allow Lilly to leverage OpenAI's generative AI to invent novel antimicrobials to treat drug-resistant pathogens.
RTTNews
|
Před 123 dny
Eli Lilly CFO Anat Ashkenazi Resigns
Eli Lilly and Co. (LLY) announced Wednesday that Anat Ashkenazi has resigned as chief financial officer to pursue a career opportunity outside of the pharmaceutical industry.
RTTNews
|
Před 143 dny
Lilly Says Phase 3 Trials Of Once-weekly Insulin In Type 2 Diabetes Meets Primary Endpoint
Eli Lilly and Co. (LLY) announced Thursday positive topline results from the QWINT-2 and QWINT-4 phase 3 clinical trials evaluating once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes using insulin for the first time (insulin naïve) and those who require multiple daily insulin injections.
RTTNews
|
Před 163 dny
Eli Lilly Boosts FY24 Outlook - Update
While reporting financial results for the first quarter on Tuesday, drugmaker Eli Lilly and Co. (LLY) raised its earnings, adjusted earnings and revenue guidance for the full-year 2024, primarily driven by the strong performance of Mounjaro and Zepbound and greater visibility into the company's production expansion for the remainder of the year.
RTTNews
|
Před 179 dny
Eli Lilly Q4 Results Top Estimates
Drugmaker Eli Lilly reported Tuesday a profit for the fourth quarter that grew 13 percent from last year, reflecting strong Mounjaro sales and higher realized prices. Both adjusted earnings per share and revenues topped analysts' expectations. The company also provided strong revenue guidance for the full-year 2024.
RTTNews
|
Před 263 dny
Eli Lilly Guides FY24 Revenues Above Estimates - Update
While reporting financial results for the fourth quarter on Tuesday, drugmaker Eli Lilly and Co. (LLY) initiated its earnings, adjusted earnings and revenue guidance for the full-year 2024.
RTTNews
|
Před 263 dny
Eli Lilly To Construct A New $2.5 Billion High-tech Manufacturing Site In Alzey, Germany
Eli Lilly and Co. (LLY) announced Friday plans to construct a new $2.5 billion high-tech manufacturing site in Alzey, Rhineland-Palatinate, Germany. This will further expand the company's global parenteral (injectable) product and device manufacturing network.
RTTNews
|
Před 344 dny
Eli Lilly Sues Clinics Over Unauthorized Mounjaro Drug Sale
Eli Lilly has filed lawsuits against several medical spas, wellness centers and compounding pharmacies for unauthorized sale of diabetes drug Mounjaro (tirzepatide). These clinics allegedly use the drug for weight loss treatment. Mounjaro, approved for type 2 diabetes, is only available from and manufactured by Lilly. They are commercially available in a pre-filled single-dose pen only.
RTTNews
|
Před 402 dny
